| answer text |
<p>We are aware that there have been supply constraints with olanzapine 210 milligram,
300 milligram, and 405 milligram powder and solvent for prolonged release suspension
for injection. We worked with manufacturers to uplift production, and the issues were
resolved in February 2024. We worked with NHS England to issue national communications
containing advice on how to manage patients whilst there was a disruption to supply.
We are not aware of any supply issues affecting oral presentations of olanzapine,
or of any supply issues with any risperidone or haloperidol products.</p>
|
 |
